| Nome |
# |
|
Emerging therapies for acute myeloid leukaemia using hDHODH inhibitors able to restore in vitro and in vivo myeloid differentiation, file e27ce42e-e3ed-2581-e053-d805fe0acbaa
|
4.588
|
|
Emerging therapies for acute myeloid leukaemia using hDHODH inhibitors, file e27ce42e-e3f2-2581-e053-d805fe0acbaa
|
1.370
|
|
HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC)., file e27ce426-eda7-2581-e053-d805fe0acbaa
|
481
|
|
A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients., file e27ce429-f428-2581-e053-d805fe0acbaa
|
340
|
|
Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy, file e27ce42a-4fba-2581-e053-d805fe0acbaa
|
310
|
|
A comparative study of myocardial molecular phenotypes of two tfr2β null mice: Role in ischemia/reperfusion, file e27ce429-0488-2581-e053-d805fe0acbaa
|
293
|
|
Improvement of in vivo pharmacokinetic profile of M433, a potent and innovative hDHODH inhibitor., file e27ce42f-3286-2581-e053-d805fe0acbaa
|
276
|
|
Two novel mutations in the tmprss6 gene associated with iron-refractory iron-deficiency anaemia (irida) and partial expression in the heterozygous form, file e27ce429-8636-2581-e053-d805fe0acbaa
|
275
|
|
Morgana acts as an oncosuppressor in chronic myeloid leukemia., file e27ce42a-6732-2581-e053-d805fe0acbaa
|
272
|
|
Analysis of microsatellite instability in chronic lymphoproliferative disorders, file e27ce42b-3152-2581-e053-d805fe0acbaa
|
271
|
|
Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034, file e27ce429-c918-2581-e053-d805fe0acbaa
|
245
|
|
Comparison of 3 Tfr2-deficient murine models suggestsdistinct functions for Tfr2-alpha and Tfr2-beta isoforms in different tissues, file e27ce426-c1c0-2581-e053-d805fe0acbaa
|
232
|
|
Expressional changes in stemness markers post electrochemotherapy in pancreatic cancer cells, file e27ce42e-1521-2581-e053-d805fe0acbaa
|
229
|
|
Distribution of Ha-RAS-1 proto-oncogene alleles in breast cancer patients and in a control population, file e27ce428-9c5b-2581-e053-d805fe0acbaa
|
226
|
|
Erythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic anemia with transfusion requirement and iron overload: a FISM Italian multicenter retrospective study, file e27ce42d-f1f6-2581-e053-d805fe0acbaa
|
225
|
|
Synergistic effect of eltrombopag and deferasirox in aplastic anemia: a clinical case and review of the literature, file e27ce42f-7039-2581-e053-d805fe0acbaa
|
222
|
|
Early prediction of treatment outcome in acute myeloid leukemia by measurment of WT1 transcript levels in peripheral blood samples collected after chemotherapy, file e27ce426-ae04-2581-e053-d805fe0acbaa
|
210
|
|
Non-Oncogene Addiction to BRD in CLL: from JQ1 Response to Resistence, file e27ce429-e86f-2581-e053-d805fe0acbaa
|
192
|
|
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy., file e27ce42a-2798-2581-e053-d805fe0acbaa
|
189
|
|
BCR-ABL inactivates cytosolic PTEN through casein kinase II mediated tail phosphorylation, file e27ce42a-4ddf-2581-e053-d805fe0acbaa
|
188
|
|
Variable but consistent pattern of Meningioma 1 gene (MN1) expression in different genetic subsets of acute myelogenous leukaemia and its potential use as a marker for minimal residual disease detection, file e27ce42a-2478-2581-e053-d805fe0acbaa
|
184
|
|
The BCR-ABL/NF-κB signal transduction network: a long lasting relationship in Philadelphia positive Leukemias, file e27ce429-d9af-2581-e053-d805fe0acbaa
|
175
|
|
The choice of first-line chronic myelogenous leukemia treatment, file e27ce42a-98df-2581-e053-d805fe0acbaa
|
174
|
|
Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias, file e27ce42a-755d-2581-e053-d805fe0acbaa
|
166
|
|
Present results and future perspectives in optimizing chronic myeloid leukemia therapy, file e27ce42d-ff33-2581-e053-d805fe0acbaa
|
163
|
|
Detection of BCR-ABL T315I mutation by peptide nucleic acid directed PCR clamping and by peptide nucleic acid FISH, file e27ce428-c072-2581-e053-d805fe0acbaa
|
162
|
|
Transferrin Receptor 2 Dependent Alterations of Brain Iron Metabolism Affect Anxiety Circuits in the Mouse, file e27ce42a-d05d-2581-e053-d805fe0acbaa
|
162
|
|
A novel assay to detect calreticulin mutations in myeloproliferative neoplasms, file e27ce42a-ff22-2581-e053-d805fe0acbaa
|
161
|
|
BCR-ABL Promotes PTEN Downregulation in Chronic Myeloid Leukemia., file e27ce42a-618c-2581-e053-d805fe0acbaa
|
160
|
|
The erythroid function of transferrin receptor 2 revealed by Tmprss6 inactivation in different models of transferrin receptor 2 knockout mice, file e27ce429-9b3c-2581-e053-d805fe0acbaa
|
157
|
|
Recommendations for the Management of CML in the Era of Second-Generation TKIs, file e27ce42a-d161-2581-e053-d805fe0acbaa
|
157
|
|
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily, file e27ce42a-38ed-2581-e053-d805fe0acbaa
|
153
|
|
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways, file e27ce42d-c9ac-2581-e053-d805fe0acbaa
|
149
|
|
ERYTHROFERRONE EXPRESSION LEVELS IN MYELODYSPLATIC SYNDROMES SHOW CLINICAL RELEVANCE, file e27ce42b-ba54-2581-e053-d805fe0acbaa
|
146
|
|
Design and application of a novel PNA probe for the detection at single cell level of JAK2V617F mutation in Myeloproliferative Neoplasms, file e27ce42a-484f-2581-e053-d805fe0acbaa
|
144
|
|
Altered Erythropoiesis in Mouse Models of Type 3 Hemochromatosis, file e27ce42b-891c-2581-e053-d805fe0acbaa
|
144
|
|
The targetable role of herpes virus-associated ubiquitin-specific protease (HAUSP) in p190 BCR-ABL leukemia, file e27ce42a-9fca-2581-e053-d805fe0acbaa
|
135
|
|
The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phase, file e27ce429-d727-2581-e053-d805fe0acbaa
|
134
|
|
Characterization of human mitochondrial ferritin promoter: Identification of transcription factors and evidences of epigenetic control, file e27ce42a-a866-2581-e053-d805fe0acbaa
|
134
|
|
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome, file e27ce42a-1d2a-2581-e053-d805fe0acbaa
|
133
|
|
Deferasirox-dependent iron chelation enhances mitochondrial dysfunction and restores p53 signaling by stabilization of p53 family members in leukemic cells, file e27ce430-ba33-2581-e053-d805fe0acbaa
|
133
|
|
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia, file e27ce42a-b5ef-2581-e053-d805fe0acbaa
|
132
|
|
A European spectrum of pharmacogenomic biomarkers: Implications for clinical pharmacogenomics, file e27ce42c-19af-2581-e053-d805fe0acbaa
|
132
|
|
The synergism between DHODH inhibitors and dipyridamole leads to metabolic lethality in acute myeloid leukemia, file e27ce432-269b-2581-e053-d805fe0acbaa
|
132
|
|
Chronic myeloid leukemia: Room for improvement?, file e27ce42e-41e0-2581-e053-d805fe0acbaa
|
130
|
|
The Wilms' tumor (WT1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapy, file e27ce429-fdab-2581-e053-d805fe0acbaa
|
128
|
|
Development of cellular and humoral response against WT1 protein vaccination in mice, file e27ce428-c9cf-2581-e053-d805fe0acbaa
|
126
|
|
Genetic Screening for Potential New Targets in Chronic Myeloid Leukemia Based on Drosophila Transgenic for Human BCR-ABL1, file e27ce431-2566-2581-e053-d805fe0acbaa
|
126
|
|
The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome Imatinib resistance, file e27ce426-b88d-2581-e053-d805fe0acbaa
|
125
|
|
A new BCR-ABL1 Drosophila model as a powerful tool to elucidate the pathogenesis and progression of chronic myeloid leukemia, file e27ce42e-45e0-2581-e053-d805fe0acbaa
|
122
|
|
New alternative splicing BCR/ABL-OOF shows an oncogenic role by lack of inhibition of BCR GTPase activity and an increased of persistence of Rac activation in chronic myeloid leukemia, file e27ce427-d673-2581-e053-d805fe0acbaa
|
121
|
|
Nilotinib in the treatment of chronic myeloid leukemia, file e27ce42e-210f-2581-e053-d805fe0acbaa
|
121
|
|
CALR-positive myeloproliferative disorder in a patient with Ph-positive chronic myeloid leukemia in durable treatment-free remission: a case report, file e27ce42d-4982-2581-e053-d805fe0acbaa
|
115
|
|
Mechanisms of p53 Functional De-Regulation: Role of the IκB-α/p53 Complex, file e27ce42a-c69f-2581-e053-d805fe0acbaa
|
112
|
|
Nanocarriers as magic bullets in the treatment of leukemia, file e27ce430-bb59-2581-e053-d805fe0acbaa
|
104
|
|
Nilotinib 300 mg twice daily: An academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients, file e27ce42e-00da-2581-e053-d805fe0acbaa
|
102
|
|
A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia, file e27ce42e-1c4c-2581-e053-d805fe0acbaa
|
101
|
|
Effects of erythropoiesis-stimulating agents on overall survival of international prognostic scoring system low/intermediate-1 risk, transfusion-inde-pendent myelodysplastic syndrome patients: A cohort study, file e27ce42e-58a4-2581-e053-d805fe0acbaa
|
100
|
|
Managing chronic myeloid leukemia for treatment-free remission: A proposal from the GIMEMA CML WP, file e27ce42f-5279-2581-e053-d805fe0acbaa
|
100
|
|
Inhibition of bromodomain and extra-terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia, file e27ce42f-2687-2581-e053-d805fe0acbaa
|
98
|
|
Standardization of BCR-ABL1 p210 Monitoring: From Nested to Digital PCR, file e27ce430-8e47-2581-e053-d805fe0acbaa
|
97
|
|
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants, file e27ce42e-3e40-2581-e053-d805fe0acbaa
|
96
|
|
Specific Monoclonal Antibody Against Bcr/Abl Out-of-Frame Alternative Proteins as Diagnostic Tool in Chronic Myelogenous Leukemia Patients, file e27ce42e-2011-2581-e053-d805fe0acbaa
|
93
|
|
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia, file e27ce42c-18ce-2581-e053-d805fe0acbaa
|
91
|
|
LOSS OF HLA-A IN ACUTE MYELOID LEUKEMIA TRANSMITTED BY THE DONOR TO LIVER AND KIDNEY GRAFT RECIPIENTS, file e27ce431-34e5-2581-e053-d805fe0acbaa
|
91
|
|
Precision tyrosine kinase inhibitor dosing in chronic myeloid leukemia?, file e27ce42e-1c48-2581-e053-d805fe0acbaa
|
90
|
|
Highly Sensitive Detection of IDH2 Mutations in Acute Myeloid Leukemia, file e27ce42f-8fea-2581-e053-d805fe0acbaa
|
89
|
|
Reduced Expression of Sprouty1 Contributes to the Aberrant Proliferation and Impaired Apoptosis of Acute Myeloid Leukemia Cells, file e27ce42e-93f2-2581-e053-d805fe0acbaa
|
88
|
|
Iron overload alters the energy metabolism in patients with myelodysplastic syndromes: results from the multicenter FISM BIOFER study, file e27ce42f-cf82-2581-e053-d805fe0acbaa
|
88
|
|
Digital PCR in Myeloid Malignancies: Ready to Replace Quantitative PCR?, file e27ce42d-fd7e-2581-e053-d805fe0acbaa
|
86
|
|
Novel Multiplex Droplet Digital PCR Assays to Monitor Minimal Residual Disease in Chronic Myeloid Leukemia Patients Showing Atypical BCR-ABL1 Transcripts, file e27ce42f-c6f4-2581-e053-d805fe0acbaa
|
85
|
|
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study, file e27ce42e-58a8-2581-e053-d805fe0acbaa
|
84
|
|
Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale, file e27ce42e-00dc-2581-e053-d805fe0acbaa
|
83
|
|
Transplantation Induces Profound Changes in the Transcriptional Asset of Hematopoietic Stem Cells: Identification of Specific Signatures Using Machine Learning Techniques, file e27ce430-0b95-2581-e053-d805fe0acbaa
|
83
|
|
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia, file e27ce42e-2012-2581-e053-d805fe0acbaa
|
82
|
|
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia, file e27ce42d-ff32-2581-e053-d805fe0acbaa
|
81
|
|
Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios, file e27ce42e-2014-2581-e053-d805fe0acbaa
|
81
|
|
Early response does not predict outcome in children and adolescents with chronic myeloid leukaemia treated with high-dose imatinib, file e27ce42e-2875-2581-e053-d805fe0acbaa
|
80
|
|
First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI, file e27ce42e-4726-2581-e053-d805fe0acbaa
|
80
|
|
PROCEEDINGS OF THE MERCK & ELSEVIER YOUNG CHEMISTSSYMPOSIUM, file e27ce42d-c4a1-2581-e053-d805fe0acbaa
|
79
|
|
Use of a DNA probe in the diagnosis of enzootic bovine leukemia, file e27ce426-e8fd-2581-e053-d805fe0acbaa
|
76
|
|
Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms, file e27ce42e-3f83-2581-e053-d805fe0acbaa
|
73
|
|
Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes IκBα mediated p53 nuclear exclusion, file e27ce427-73f5-2581-e053-d805fe0acbaa
|
71
|
|
Dasatinib dose management for the treatment of chronic myeloid leukemia, file e27ce42e-4725-2581-e053-d805fe0acbaa
|
70
|
|
Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms, file e27ce42e-00d6-2581-e053-d805fe0acbaa
|
66
|
|
Clinical significance of TFR2 and EPOR expression in bone marrow cells in myelodysplastic syndromes, file e27ce42a-4f6b-2581-e053-d805fe0acbaa
|
64
|
|
ROCK AS THERAPEUTICAL TARGET FOR MORGANA LOW CML, file e27ce428-fd5b-2581-e053-d805fe0acbaa
|
62
|
|
ROLE OF HAUSP/PTEN NETWORK IN CHRONIC LYMPHOID LEUKEMIA PATHOGENESIS AND THERAPY, file e27ce427-7a87-2581-e053-d805fe0acbaa
|
61
|
|
Untangling the functional roles of a large HERC1 E3-Ubiquitin Ligase in Dictyostelium and Leukemic Cells., file e27ce42f-815d-2581-e053-d805fe0acbaa
|
52
|
|
The Giant HECT E3 Ubiquitin Ligase HERC1 Is Aberrantly Expressed in Myeloid Related Disorders and It Is a Novel BCR-ABL1 Binding Partner, file e27ce431-f2e9-2581-e053-d805fe0acbaa
|
52
|
|
Alignment of Qx100/Qx200 Droplet Digital (Bio-Rad) and QuantStudio 3D (Thermofisher) Digital PCR for Quantification of BCR-ABL1 in Ph+ Chronic Myeloid Leukemia, file e27ce432-1025-2581-e053-d805fe0acbaa
|
52
|
|
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program, file e27ce427-b524-2581-e053-d805fe0acbaa
|
50
|
|
To Swab or Not to Swab? The Lesson Learned in Italy in the Early Stage of the COVID-19 Pandemic, file e27ce432-1c39-2581-e053-d805fe0acbaa
|
50
|
|
Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors, file e27ce433-402c-2581-e053-d805fe0acbaa
|
49
|
|
NOVEL HUMAN DIHYDROOROTATE DEHYDROGENASE (HDHODH) INHIBITORS AND THEIR USE IN TARGETING ONCOLOGICAL DISEASES SENSITIVE TO PYRIMIDINE STARVATION, file e27ce42e-cc6b-2581-e053-d805fe0acbaa
|
48
|
|
A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation, file e27ce432-8806-2581-e053-d805fe0acbaa
|
46
|
|
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice, file e27ce430-0dcb-2581-e053-d805fe0acbaa
|
45
|
|
INHIBITION OF USP7 INDUCES SELECTIVE CANCER CELL DEATH IN CHRONIC LYMPHOCYTIC LEUKEMIA THROUGH PTEN AND INDEPENDENTLY FROM P53 STATUS, file e27ce429-031a-2581-e053-d805fe0acbaa
|
44
|
|
ALTERNATIVE SPLICING VARIANT COULD BE RESPONSIBLE OF MORGANA
UNDER-EXPRESSION IN ACML, file e27ce427-7a8b-2581-e053-d805fe0acbaa
|
43
|
|
Droplet Digital PCR for BCR–ABL1 Monitoring in Diagnostic Routine: Ready to Start?, file e27ce433-35d6-2581-e053-d805fe0acbaa
|
42
|
| Totale |
18.930 |